AtriCure Q2 revenue beats estimates

AtriCure

29/07/2025 21:08

Overview

AtriCure Q2 revenue rises 17.1% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 beats estimates, improving to a loss of $0.02

Adjusted EBITDA increases significantly, surpassing analyst forecasts, per LSEG data

Outlook

AtriCure projects full-year 2025 revenue between $527 mln and $533 mln

Company expects full-year 2025 adjusted EBITDA of $49 mln to $52 mln

AtriCure anticipates full-year 2025 adjusted loss per share of $0.34 to $0.39

Company expects modest cash flow generation for full-year 2025

Result Drivers

PRODUCT ADOPTION - Revenue growth driven by increased adoption of AtriCure's Afib, LAA management, and post-operative pain management products

KEY PRODUCT LINES - U.S. revenue boosted by sales of AtriClip FLEX·Mini, EnCompass clamp, and cryoSPHERE MAX probe

INTERNATIONAL GROWTH - Significant international revenue increase across all franchises and geographic regions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$136.10 mln
$130.20 mln (9 Analysts)
Q2 Adjusted EPS
Beat
-$0.02
-$0.17 (9 Analysts)
Q2 Adjusted EBITDA
Beat
$15.40 mln
$10.10 mln (7 Analysts)
Q2 Gross Margin
74.5%
Q2 Gross Profit
$101.50 mln
Q2 Operating Income
-$6.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for AtriCure Inc is $50.50, about 34.2% above its July 28 closing price of $33.22

Press Release: ID:nBw8X0X7Va

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)